ITI-214
- Generic Name
- ITI-214
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26FN7O
- CAS Number
- 1160521-50-5
- Unique Ingredient Identifier
- 3GBO34D1BE
- Background
ITI-214 is under investigation in clinical trial NCT03489772 (Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement).
- Associated Conditions
- -
- Associated Therapies
- -
Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT03489772
- Locations
- 🇺🇸
Laureate Institute for Brain Research, Inc., Tulsa, Oklahoma, United States
Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03387215
- Locations
- 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03257046
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Duke Early Phase Research Unit, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath